

Zu der Bilanz:

- Ende März 2012: 17,5 Mio USD Cash
- Kapitalerhöhung im Juli 2012, + 34,5 Mio USD, d.h. Omeros hat jetzt ca. 51 Mio USD Cash
- Quartalsverlust Q1/2012: ca. 8.9 Mio USD ⇒ Omeros ist für die nächste Zeit gut finanziert!

Zur Pipeline:

- **Zwei Produkte in Phase III; Ergebnisse werden in H2/2012 erwartet**
- "OMS302, one of Omeros' proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. In the first Phase 3 clinical trial of OMS302, the drug product demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis ($p < 0.00001$) and reduction of postoperative pain ($p < 0.00001$). Omeros is now conducting the second Phase 3 clinical trial, which is expected to enroll approximately 400 patients. This trial will evaluate the same efficacy and safety measures as the earlier successful Phase 2b and Phase 3 clinical trials."..." Analysts from Wedbush Morgan Securities, one of the few analysts to cover Omeros, have now pencilled in global sales of \$125m for OMS302 in 2015, although others presume that the candidate will be outlicensed."
- **Vier weitere Programme starten demnächst (H2/ 2012 oder H1/2013) das Phase I Programm.**
- **Omeros hat eine High.-Throughput Technology um kleine Moleküle gegen G-Protein coupled receptors zu finden und ist dabei sehr erfolgreich.**
- Omeros uses its proprietary high-throughput cellular redistribution assay (CRA) to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.